These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 27392166)
21. Comment on the use of computational models to study the effect of apixaban and rivaroxaban on thrombin generation. Kremers RM; Wagenvoord RJ; Hemker HC Thromb Haemost; 2016 Apr; 115(4):869-70. PubMed ID: 26467386 [No Abstract] [Full Text] [Related]
22. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120 [TBL] [Abstract][Full Text] [Related]
23. Heavy menstrual bleeding on rivaroxaban. Ferreira M; Barsam S; Patel JP; Czuprynska J; Roberts LN; Patel RK; Arya R Br J Haematol; 2016 Apr; 173(2):314-5. PubMed ID: 26212626 [No Abstract] [Full Text] [Related]
24. Dosing-time-dependent effect of rivaroxaban on coagulation activity in rats. Fujiwara Y; Ando H; Ushijima K; Horiguchi M; Yamashita C; Fujimura A J Pharmacol Sci; 2017 Aug; 134(4):234-238. PubMed ID: 28844423 [TBL] [Abstract][Full Text] [Related]
25. Laboratory monitoring of rivaroxaban and assessment of its bleeding risk. Zhang Y; Qian Q; Qian G; Sun G Br J Biomed Sci; 2016 Jul; 73(3):134-139. PubMed ID: 27400196 [TBL] [Abstract][Full Text] [Related]
26. Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation. Kauffmann S; Chabanne R; Coste A; Longeras F; Sinegre T; Schmidt J; Samama CM; Constantin JM; Lebreton A A A Case Rep; 2015 Jun; 4(11):151-4. PubMed ID: 26035221 [TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban shows promise as effective therapy for cancer patients with venous thromboembolic disease. Theberge I; Bowdridge J; Forgie MA; Carrier M; Louzada M; Siquiera L; Rhodes M; Wells PS Thromb Res; 2017 Apr; 152():4-6. PubMed ID: 28192715 [No Abstract] [Full Text] [Related]
28. In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. Barco S; Whitney Cheung Y; Coppens M; Hutten BA; Meijers JC; Middeldorp S Br J Haematol; 2016 Jan; 172(2):255-61. PubMed ID: 26488126 [TBL] [Abstract][Full Text] [Related]
29. Routine coagulation test abnormalities caused by rivaroxaban: A case report. Song Z; Wu H; Cao H; Yang S; Tang M; Qin L Medicine (Baltimore); 2018 Nov; 97(45):e13104. PubMed ID: 30407322 [TBL] [Abstract][Full Text] [Related]
30. Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme. Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jacquemin M; Jochmans K; Mullier F; Wijns W; China B; Vernelen K; Soumali MR Int J Lab Hematol; 2017 Aug; 39(4):402-408. PubMed ID: 28304137 [TBL] [Abstract][Full Text] [Related]
31. [Monitoring options and reversal agents for oral anticoagulants]. Thorup SB; Husted SE; Vang ML Ugeskr Laeger; 2014 Apr; 176(9):. PubMed ID: 25096568 [TBL] [Abstract][Full Text] [Related]
32. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Baglin T; Keeling D; Kitchen S; Br J Haematol; 2012 Nov; 159(4):427-9. PubMed ID: 22970737 [No Abstract] [Full Text] [Related]
33. Assays for measuring rivaroxaban: their suitability and limitations. Lindhoff-Last E; Samama MM; Ortel TL; Weitz JI; Spiro TE Ther Drug Monit; 2010 Dec; 32(6):673-9. PubMed ID: 20844464 [TBL] [Abstract][Full Text] [Related]
34. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide. Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969 [TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban for the treatment of cerebral venous thrombosis. Mutgi SA; Grose NA; Behrouz R Int J Stroke; 2015 Oct; 10 Suppl A100():167-8. PubMed ID: 26502976 [No Abstract] [Full Text] [Related]
36. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial. Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613 [TBL] [Abstract][Full Text] [Related]
37. Clinically relevant interaction of rivaroxaban and valproic acid - A case report. Langenbruch L; Meuth SG; Wiendl H; Mesters R; Möddel G Seizure; 2020 Aug; 80():46-47. PubMed ID: 32521502 [No Abstract] [Full Text] [Related]
38. Use of Rivaroxaban for Mesenteric Vein Thrombosis Secondary to Diverticulitis: A Case Report. Parthvi R; Mehra S Am J Ther; 2017; 24(5):e629-e630. PubMed ID: 27759584 [No Abstract] [Full Text] [Related]
39. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients. Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320 [TBL] [Abstract][Full Text] [Related]
40. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Mani H; Hesse C; Stratmann G; Lindhoff-Last E Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]